A Seattle biotech offloads lead eye drug in deal valued at $1B+ as it refocuses on emerging pipeline

An FDA-approved drug used to maintain pupil size in patients during cataract surgery and reduce postoperative eye pain has been sold to Rayner Surgical in a deal that could exceed $1 billion after milestones.